Antimicrobial Drugs: Mechanisms, Testing, Safety, and Resistance

Study Guide - Smart Notes

Tailored notes based on your materials, expanded with key definitions, examples, and context.

Antimicrobial Drugs

Major Milestones in Antimicrobial Therapy

Antimicrobial therapy has evolved through key discoveries and innovations, each contributing to the development of effective treatments for infectious diseases.

Paul Ehrlich and the "Magic Bullet" Concept: Introduced the idea of selective toxicity—chemicals that target pathogens without harming the host. His arsenic-based compounds treated Treponema pallidum (syphilis), though toxicity limited their use.
Alexander Fleming's Discovery of Penicillin (1928): Observed that a mold (Penicillium) produced a substance inhibiting bacterial growth, leading to the development of penicillin as the first widely used antibiotic.
Gerhard Domagk and Sulfonamides (1930s): Developed the first practical synthetic antimicrobial drugs, expanding treatment options for bacterial infections.
Selman Waksman and Soil Microbes: Identified soil microorganisms as sources of antibiotics and coined the term "antibiotic." This discovery broadened the search for new antimicrobial agents.
Semisynthetic and Synthetic Agents: Chemical modification and laboratory synthesis have improved drug properties such as stability, absorption, and activity.

Key Vocabulary: Antimicrobial: agent against microbes. Antibiotic: originally a naturally produced antimicrobial, now commonly used for antibacterial drugs. Semisynthetic: natural antibiotic chemically modified. Synthetic: made entirely in a laboratory.

Selective Toxicity

Selective toxicity refers to a drug's ability to harm the pathogen more than the host. The best drug targets are structures or processes unique to microbes or sufficiently different from human counterparts.

Bacteria: Many differences from humans (e.g., peptidoglycan cell walls, 70S ribosomes) allow for selective targeting.
Fungi: Fungal cells are eukaryotic, sharing many features with human cells, making selective toxicity more challenging. Fungal cell walls and membrane sterols are potential targets.
Protozoa: Also eukaryotic, with limited unique targets.
Helminths: Parasitic animals with many similarities to humans; drugs must exploit subtle differences.
Viruses: Replicate inside host cells, using host machinery; few unique targets are available.

Bacteriostatic drugs inhibit bacterial growth, while bactericidal drugs kill bacteria. The effect can depend on drug concentration, organism, and conditions.

Mechanisms of Antimicrobial Action

Antimicrobial drugs act through six main mechanisms, each targeting a vital microbial process:

Inhibit Cell Wall Synthesis: Prevents formation of functional cell walls, leading to cell lysis. Human cells lack cell walls, providing selectivity.
Inhibit Protein Synthesis: Interferes with translation or related steps. Bacterial 70S ribosomes differ from human 80S ribosomes.
Disrupt Cytoplasmic Membranes: Damages membrane integrity, causing leakage and loss of essential gradients. Selectivity depends on membrane differences.
Inhibit Metabolic Pathways: Blocks essential biochemical reactions, often by mimicking substrates or inhibiting enzymes.
Inhibit Nucleic Acid Synthesis: Interferes with DNA replication or RNA transcription, halting growth or replication.
Prevent Viral Attachment, Entry, or Uncoating: Blocks steps required for viruses to infect host cells.

Memory cue: wall, proteins, membrane, metabolism, nucleic acids, viral entry.

Characteristics of Effective Antimicrobial Agents

An effective antimicrobial agent should:

Exhibit selective toxicity at achievable concentrations.
Be active against the causative organism.
Reach the infection site in sufficient concentration.
Remain active long enough to be effective.
Have an appropriate route and dosing schedule.
Cause minimal toxicity, allergy, and disruption of normal microbiota.
Have a useful safety margin and low risk of resistance development.

Note: Laboratory activity does not guarantee clinical success; tissue penetration and patient factors are crucial.

Spectrum of Activity and Susceptibility Testing

Narrow vs. Broad Spectrum

Feature	Narrow Spectrum	Broad Spectrum
Coverage	Limited group of microbes	Many types of microbes
Advantage	Targets known pathogen, spares normal flora	Useful for uncertain causes or mixed infections
Limitation	May miss pathogens outside range	Disrupts more normal microbiota, increases resistance risk

Additional info: Broad spectrum does not mean stronger; unnecessary use increases selection pressure for resistance.

Diffusion Susceptibility Testing (Kirby-Bauer)

The Kirby-Bauer test assesses bacterial susceptibility to antibiotics using agar diffusion:

Spread standardized bacterial sample over agar to form a bacterial lawn.
Place disks with known drug amounts on the agar.
Incubate; drugs diffuse outward.
Measure the zone of inhibition (clear area with no growth) in millimeters.
Interpret results using drug- and organism-specific tables:

Result	Meaning
Susceptible (S)	Likely to respond to drug
Intermediate (I)	Response uncertain; may require higher exposure
Resistant (R)	Unlikely to respond at normal doses

Critical point: The largest zone is not always best; diffusion rates differ for each drug.

MIC, Etest, and MBC

These tests determine the minimum concentrations needed to inhibit or kill bacteria:

MIC (Minimum Inhibitory Concentration): Lowest concentration preventing visible growth. Determined by serial dilutions in broth.
Etest: Uses a gradient strip on agar; read MIC where the inhibition ellipse meets the strip.
MBC (Minimum Bactericidal Concentration): Lowest concentration that kills bacteria. Determined by transferring samples from MIC tubes to drug-free media and checking for growth.

Drug concentration	Growth in broth	Growth after transfer
1 µg/mL	Yes	Not tested
2 µg/mL	Yes	Not tested
4 µg/mL	No	Yes
8 µg/mL	No	No
16 µg/mL	No	No

MIC = 4 µg/mL (first concentration with no visible growth). MBC = 8 µg/mL (first concentration with no recovery on drug-free agar).

Memory cue: MIC = inhibit; MBC = kill. MBC is usually equal to or higher than MIC.

Equation:

Administration and Safety

Systemic Routes of Administration

Route	Advantages	Disadvantages
Oral	Convenient, inexpensive, self-administered	Variable absorption, affected by food/digestion, missed doses
Intramuscular (IM)	Bypasses digestive tract, slow release possible	Painful, absorption depends on circulation, limited volume
Intravenous (IV)	Direct to bloodstream, rapid and predictable	Requires vascular access, risk of complications, rapid adverse effects

Topical administration is used for local external infections.

Categories of Side Effects

Toxicity: Direct harm to organs (e.g., kidneys, liver, nerves).
Allergies: Immune reactions from mild to severe (anaphylaxis).
Disruption of Normal Microbiota: Loss of protective microbes can allow opportunistic infections (e.g., yeast overgrowth after antibiotics).

Therapeutic Index and Therapeutic Window

The therapeutic index (TI) measures drug safety:

TD50: Dose toxic to 50% of the population.
ED50: Dose effective in 50% of the population.

A higher TI indicates a larger safety margin. The therapeutic window is the range of concentrations effective without excessive toxicity.

Microbial Resistance

Mechanisms of Microbial Resistance

Microbes can resist drugs through seven main mechanisms:

Destroy or Inactivate the Drug: Enzymes break down or modify the drug (e.g., beta-lactamases).
Reduce Drug Entry: Altered permeability or porins prevent drug access.
Alter the Drug Target: Structural changes reduce drug binding.
Alter Metabolic Chemistry: Bypass blocked pathways or increase enzyme production.
Pump the Drug Out: Efflux pumps remove drugs from the cell.
Form or Live Within Biofilms: Biofilms reduce drug penetration and slow metabolism.
Protect the Drug Target: Decoy or protective molecules shield the target.

Memory cue: destroy it; keep it out; change the target; bypass the step; pump it out; hide in a biofilm; protect the target.

Persister cells are slow-growing or inactive cells that survive drug exposure without inherited resistance, contributing to chronic infections.

Development and Spread of Resistance

Resistance arises and spreads through selection and gene transfer:

Populations contain both susceptible and resistant cells.
Resistance arises via mutation or acquisition of resistance genes.
Drug exposure suppresses susceptible cells; resistant cells survive and proliferate.
Resistant cells become more common.

R plasmids carry multiple resistance genes and can spread via:

Conjugation: Direct cell-to-cell transfer.
Transformation: Uptake of DNA from the environment.
Transduction: Transfer by bacteriophages.

Multiple resistance: Resistance to several antimicrobial types (often three or more). Cross resistance: One mechanism confers resistance to multiple related drugs.

Strategies to Reduce Resistance Development

Use antimicrobials only when indicated; avoid for viral infections.
Identify pathogens and use susceptibility results when possible.
Choose appropriate, effective agents and narrow coverage when suitable.
Follow prescribed dose, schedule, and duration.
Avoid sharing drugs or saving leftovers.
Prevent infection and transmission (hygiene, vaccination, infection control).
Use combination therapy when indicated.
Support stewardship, surveillance, and new therapy development.

Synergism: Drug combination is more effective than either alone. Antagonism: One drug reduces another's effect.

Key Reminders and Self-Check

Narrow spectrum describes coverage, not weakness.
An inhibition zone means no visible growth, not proven killing.
MIC inhibits; MBC kills.
Lab susceptibility must be paired with adequate exposure at the infection site.
High TI generally means a wider margin of safety.
Resistance is selected and spread through genes; persistence may be temporary tolerance.